Trial design and participants
TB, impaired liver or renal function, extra-pulmonary TB, allergy, pulmonary lesion
ALLERGY
This was a prospective, randomized, parallel group, controlled, open-label pilot clinical trial conducted at the Shanghai Pulmonary Hospital, one of the largest TB-designated hospitals in China. Patients with newly diagnosed bacteriologically-confirmed pulmonary TB were screened for eligibility from December 1 2017 to December 31 2019. Apart from bacteriological evidence, participants should age 18–65 years and have a typical pulmonary lesion of TB by radiological examination. Those received any anti-TB treatment within 6 months preceding initiation of the study drugs; were pregnant or lactating women; had impaired liver or renal function; had a history of allergy or intolerance to any of the study drugs; were diagnosed with extra-pulmonary TB, drug-resistant TB or 